GOL Linhas Aereas Inteligentes S.A. (GOL - Free Report) reported air traffic figures for April 2019. Traffic, measured in revenue passenger kilometers (RPK), climbed 7.8% to 2.98 billion. While international RPK surged 36.9%, domestic RPK grew 4.3% in the month.
On a year-over-year basis, consolidated capacity (or available seat kilometers/ASKs) was up 6.7% to 3.69 billion, primarily on 31.1% expansion in international capacity. Moreover, the carrier witnessed a 6.2% increase in passenger count in April.
Load factor, percentage of seats filled by passengers, inched up to 80.8% from 80% a year ago as traffic growth exceeded capacity expansion.
At the end of the first four months of 2019, RPK increased 6.6% while ASK grew 5.3%. Also, load factor for the period improved 90 basis points. However, the company recorded a 0.6% dip in the volume of departures whereas the number of seats occupied by passengers was up 3.4%.
GOL Linhas recently reported first-quarter 2019 earnings numbers. The company’s adjusted earnings per share of 9 cents missed the Zacks Consensus Estimate by 24 cents. Results were hurt by 16.2% depreciation of the Brazilian real against the US dollar and high fuel costs.
Meanwhile, net revenues of R$3.2 billion improved 8.3% year over year owing to solid demand for air travel and a strong pricing. Passenger revenues accounted for bulk (94.5%) of the top line and rose 8.4% on a year-over-year basis. (Read more: Gol Linhas Misses on Q1 Earnings, Tweaks '19 & '20 View)
Zacks Rank & Key Picks
GOL Linhas carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader Transportation sector are SkyWest, Inc. (SKYW - Free Report) , Swire Pacific Ltd. (SWRAY - Free Report) and GATX Corporation (GATX - Free Report) . While SkyWest and Swire Pacific sport a Zacks Rank #1 (Strong Buy), GATX carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Shares of SkyWest, Swire Pacific and GATX have gained more than 6%, 23% and 5%, respectively, in a year’s time.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>